PLPL (Plandai Biotechnology) Cash-to-Debt: 0.00 (As of Jun. 2023)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

What is Plandai Biotechnology Cash-to-Debt?

Plandai Biotechnology PLPL -90.00% Cash-to-Debt is 0.00 as of Jun. 2023.

Cash to Debt Ratio measures the financial strength of a company. It is calculated as a company's cash, cash equivalents, and marketable securities divide by its debt. Plandai Biotechnology's cash to debt ratio for the quarter that ended in Jun. 2023 was 0.00.

If Cash to Debt ratio is less than 1, the company cannot pay off its debt using the cash in hand. Here we can see, Plandai Biotechnology couldn't pay off its debt using the cash in hand for the quarter that ended in Jun. 2023.

The historical rank and industry rank for Plandai Biotechnology's Cash-to-Debt or its related term are showing as below:

PLPL's Cash-to-Debt is not ranked *
in the Business Services industry.
Industry Median: 1.21
* Ranked among companies with meaningful Cash-to-Debt only.

Plandai Biotechnology  (OTCPK:PLPL) Cash-to-Debt Explanation

If Cash to Debt ratio is greater than 1, the company can pay off its debt using the cash in hand. If it is smaller than 1, it means the company has more debt than the cash in hands. In this case, it is important to look the the company's Interest Coverage. Ben Graham requires that a company must have an Interest Coverage of at least 5.

Plandai Biotechnology Cash-to-Debt Related Terms

Plandai Biotechnology Cash-to-Debt Historical Data

* Premium members only.

The historical data trend for Plandai Biotechnology's Cash-to-Debt can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Note: An indication of "No Debt" does not necessarily mean that the company has no debt obligations; it could be due to missing data in the quarterly or annual report. Use caution when interpreting this information.

Plandai Biotechnology Cash-to-Debt Chart

Plandai Biotechnology Annual Data
Trend Mar09 Mar10 Mar11 Jun12 Jun13 Jun14 Jun15 Jun16 Jun22 Jun23
Cash-to-Debt
Get a 7-Day Free Trial Premium Member Only Premium Member Only 0.01 0.00 0.00 0.00 0.00

Plandai Biotechnology Semi-Annual Data
Mar03 Mar04 Mar05 Mar06 Mar07 Mar08 Mar09 Mar10 Mar11 Jun12 Jun13 Jun14 Jun15 Jun16 Jun22 Jun23
Cash-to-Debt Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.01 0.00 0.00 0.00 0.00

PLPL vs CRGH, TCRI, MAYX: Cash-to-Debt Comparison

For the Specialty Business Services subindustry, Plandai Biotechnology's Cash-to-Debt, along with its competitors' market caps and Cash-to-Debt data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Plandai Biotechnology Cash-to-Debt vs Business Services Industry

For the Business Services industry and Industrials sector, Plandai Biotechnology's Cash-to-Debt distribution charts can be found below:

* The bar in red indicates where Plandai Biotechnology's Cash-to-Debt falls into.


Plandai Biotechnology Cash-to-Debt Calculation

This is the ratio of a company's Cash, Cash Equivalents, Marketable Securities to its debt. The debt includes the Short-Term Debt & Capital Lease Obligation and Long-Term Debt & Capital Lease Obligation. This ratio measures the financial strength of a company. This ratio is updated quarterly.

Plandai Biotechnology's Cash to Debt Ratio for the fiscal year that ended in Jun. 2023 is calculated as:

Cash to Debt Ratio= Cash, Cash Equivalents, Marketable Securities / Total Debt
= Cash, Cash Equivalents, Marketable Securities / (Short-Term Debt & Capital Lease Obligation + Long-Term Debt & Capital Lease Obligation)
=0 / (0.05 + 0)
=0.00

Plandai Biotechnology's Cash to Debt Ratio for the quarter that ended in Jun. 2023 is calculated as:

Cash to Debt Ratio= Cash, Cash Equivalents, Marketable Securities / Total Debt
= Cash, Cash Equivalents, Marketable Securities / (Short-Term Debt & Capital Lease Obligation + Long-Term Debt & Capital Lease Obligation)
=0 / (0.05 + 0)
=0.00

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about Cash-to-Debt →
What does a Cash-to-Debt of 0.00 mean?
Plandai Biotechnology (PLPL) has a Cash-to-Debt of 0.00 as of Jun. 2023.
Is Plandai Biotechnology's Cash-to-Debt too high?
Plandai Biotechnology's current Cash-to-Debt is 0.00.
How does Plandai Biotechnology's Cash-to-Debt compare to CRGH and TCRI?
Plandai Biotechnology's Cash-to-Debt of 0.00 can be compared against companies in the Business Services industry. The industry median Cash-to-Debt is 1.21. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Cash-to-Debt for a Business Services company?
The median Cash-to-Debt among Business Services companies is 1.21, based on 1,073 companies in the industry. Companies in the top quartile (top 25%) have a Cash-to-Debt significantly above this median, while those in the bottom quartile fall well below. However, Cash-to-Debt should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Cash-to-Debt mean?
A high Cash-to-Debt can signal that a stock is expensive relative to its fundamentals. For the Business Services industry, the median Cash-to-Debt is 1.21 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Plandai Biotechnology's current Cash-to-Debt is 0.00. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Plandai Biotechnology stock overvalued right now?
Plandai Biotechnology (PLPL) has a current Cash-to-Debt of 0.00. The current Cash-to-Debt is 0.00. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Cash-to-Debt calculated?
Cash-to-Debt is calculated from a company's financial statements. For Plandai Biotechnology (PLPL), the current Cash-to-Debt is 0.00 as of Jun. 2023. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Plandai Biotechnology Business Description

Address Xinyi Road, Sector 5, No. 7, 57th Floor - 1, Xinyi District, Taipei, TWN, 330
Plandai Biotechnology Inc is engaged in catering and catering management operations in Taiwan.